Introduction
Coronary artery disease (CAD) and acute myocardial infarction (AMI) are major causes of death and morbidity worldwide (1) . Rapid restoration of coronary blood flow to the jeopardized myocardium is the crux of therapy after AMI. The invention and usage of stents have made percutaneous coronary intervention (PCI) a safe, effective, and preferred treatment of ST-segment elevation myocardial infarction (STEMI) (2) . However, even after patency of an infarcted artery was successfully achieved via stent implantation, sufficient myocardial reperfusion was not observed in 2.3% to 29% of patients in the setting of AMI, often called the no-reflow (NRF) phenomenon (3) (4) (5) . Despite the mechanical opening of the infarct-related artery (IRA), early postinfarction complications and in-hospital long-term morbidity and mortality rates increased in patients who developed NRF (6) (7) (8) . The mechanisms of NRF are complex and multifactorial; the most probable causes include a combination of platelet aggregation, distal embolization, microvascular vasoconstriction, neutrophil plugging, and tissue edema (9) . Noninvasive markers of the NRF phenomenon may thus provide important prognostic information. Recently, one of the major issues cardiologists have been working on is risk prediction in patients with STEMI to identify NRF. (6) (7) (8) 10) . A large number of scoring systems and laboratory parameters have been used in clinical practice. Nevertheless, those interested in cardiovascular medicine still need an easily accessible, cost effective, and noninvasive predictor to carry out risk stratification by determining NRF in acute coronary syndrome (ACS) patients. In order to identify high-risk patients with ACS, various risks classification systems and scoring systems are used frequently (11) (12) (13) (14) . Prediction of early and late mortality in hundreds of thousands of patients has been shown by the in-hospital death global registry of acute coronary events (GRACE) risk score (GRS) and the thrombolysis in myocardial infarction (TIMI) risk score (TRS) (13, 14) . Recently, the TIMI risk index (TRI) (which can predict mortality, may be easier to assess and can be scored with fewer parameters in patients with non-STsegment elevation ACS (NSTE-ACS) and patients with STEMI) was improved. This index has been shown to be useful and helpful in many studies (15, 16) . Many studies have investigated the relationship between GRS, TRI, and ACS (1, (17) (18) (19) , but none have addressed the association between TRI, TRS, GRS, and NRF in patients with STEMI. We investigated whether preintervention TRI, TRS, and GRS are related to coronary NRF in patients with STEMI who underwent primary percutaneous coronary intervention (p-PCI).
Materials and methods

Study population
A total of 900 patients who presented with STEMIs and underwent p-PCI within 12 h of symptom onset between January 2012 and February 2014 were included in this retrospective study. STEMI was defined based on the criteria used by the American College of Cardiology and the European Society of Cardiology (20) : an increase in troponin I > 1 ng/mL, a new ST elevation as measured from the J-point in 2 or more contiguous leads with leads V1, V2, and V3 measuring at least 0.2 mV or at least 0.1 mV in the remaining leads during the first 12 h after symptom onset, or newly developed left bundle branch block (LBBB) pattern.
Patients with malignancy, bleeding diathesis, hematological disease, severe liver disorder, autoimmune disease, severe valvular disease, and inflammatory or infectious diseases were excluded from the study. In addition, patients on the following medications were not included in the study: corticosteroids, cytotoxic drugs, thrombolytic therapy, glycoprotein IIb/IIIa inhibitors, and diuretics. Patients who were not treated with p-PCI, did not undergo follow-up blood work, or had poor echocardiographic windows were also excluded from the investigation. As a result, a total of 371 patients formed the study group.
All patients underwent physical examination and coronary risk factor assessment through a complete medical history. Additionally, Killip class examinations of all patients were recorded (21) .
Demographic data and variables to determine TRS according to age, diabetes mellitus (DM)/hypertension (HT) or angina, heart rate of <100 bpm, systolic blood pressure (SBP) of <100 mmHg, Killip class II-IV, weight of <67 kg, anterior MI or LBBB presentation, and latency of >4 h were recorded (22) . Calculation of the TRS was performed with a computer program (http://www.mdcalc. com/timi-risk-score-for-stemi/).
The determination of GRS points including age, creatinine, heart rate, SBP, Killip class, cardiac arrest on admission, elevated cardiac markers, and ST-segment deviation were recorded (14) ; the calculation of GRS was performed using a computer program (www. outcomesumassmed.org/grace/acs_risk/acs_risk_content. html).
The TRI of patients were calculated by the formula "Heart rate × (age÷10) 2 ÷SBP". During the in-hospital follow-up period patients were monitored for major adverse cardiac events (MACEs). Cardiogenic shock, new advanced heart failure, pulmonary edema, complete atrioventricular block (AVB) requiring a temporary pacemaker, severe ventricular arrhythmia, and in-hospital mortality during the post-PCI follow-up period were regarded as MACEs. An in-hospital mortality was only considered a MACE if the death was caused by myocardial infarction, cardiac arrest, or other cardiacrelated causes. Cardiogenic shock was defined as: marked and persistent hypotension lasting more than 30 min with a SBP less than 80 mmHg and signs of hypoperfusion due to left ventricular dysfunction, right ventricular infarction, or cardiac mechanical complications. If the patient qualified for a New York Heart Association functional classification of III or greater, it was considered new-onset advanced heart failure. Severe ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation, or asystole) were considered to be MACEs if they occurred within 48 h of onset.
Blood samples and echocardiography
Venous blood samples were collected when the patient was admitted to the emergency department or intensive coronary care unit (ICCU) before p-PCI. Hematologic indices were calculated using an automated hematology analyzer system (Abbott Cell-Dyn 3700; Abbott Laboratory). Absolute cell counts were utilized to perform subsequent analyses. The neutrophil to lymphocyte ratio (NLR) was calculated as the ratio of the neutrophils and lymphocytes, both obtained from the same automated blood sample at admission. Total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, and creatinine levels were measured with the Abbott Architect C16000 autoanalyzer (Abbott Laboratory). Fasting lipid panels were obtained after an overnight fast.
Transthoracic two-dimensional echocardiography was performed upon admission to the ICCU to determine left ventricular ejection fraction, left ventricular systolic diameter, left ventricular diastolic diameter, and left atrial diameter (Vivid S6, GE Medical Systems).
Coronary angiography (TIMI and myocardial blush grade (MBG) flow)
All patients underwent selective coronary angiography using the Judkins technique. PCI procedures were performed with a standard femoral approach using a 7 Fr guiding catheter. Coronary blood flow patterns after p-PCI were subject to a thorough evaluation on the basis of TIMI flow grade, using grades 0, 1, 2, and 3 (23) . The final TIMI flow grade and MBG were assessed using standard methods. Two cardiologists who were blinded to the patients' clinical situations assessed the postprocedural TIMI flow grade of the IRA. We defined the angiographic NRF phenomenon as a coronary TIMI flow grade of ≤2 after the vessel was recanalized or TIMI flow grade 3 together with a final MBG of <2, in the same manner as described in previous studies (24, 25) . For all study participants, only one artery was identified as the IRA. CAD was defined as greater than 50% stenosis in one of the major coronary arteries.
Statistical analysis
All analyses were performed with SPSS for Windows version 18.0. Continuous variables were expressed as means ± standard deviation and categorical variables were expressed as percentages. The two-sample KolmogorovSmirnov test assessed whether continuous variables followed a normal distribution. Comparisons between categorical and continuous variables between the reflow and NRF groups were performed using the χ 2 or Fischer's exact test and independent samples t-test or MannWhitney U-test, respectively. Statistical significance was defined as P < 0.05.
Multivariate stepwise forward logistic regression analysis was used to assess independent predictors of postprocedural NRF according to MBG flow. All variables that were significant predictors were included in the logistic regression model; the results were expressed as the odds ratio (OR) with the corresponding 95% confidence interval (CI).
The study protocol was reviewed and approved by the Ethics Committee in accordance with the Declaration of Helsinki.
Results
A total of 371 patients were included in the data analysis. Of all the study participants, 17.5% according to MBG flow were in the NRF group, while the remaining were stratified into the reflow group. Baseline demographic characteristics and cardiac risk scores on admission of patients for TIMI and MBG flow after p-PCI results organized according to reflow grouping are shown in Tables 1 and 2 . No significant differences regarding known atherogenic risk factors, prehospital medication, location of STEMI, SBP, and heart rate on admission were identified between the groups. NRF patients were older than reflow patients (P < 0.018 for TIMI flow, P < 0.017 for MBG flow) and Killip class III-IV designations were more common in NRF patients (P = 0.009 for TIMI flow, P = 0.029 for MBG). TRS (P = 0.015 for TIMI flow, P = 0.043 for MBG ), GRS ( P < 0.001 for TIMI flow, P = 0.004 for MBG ), and TRI ( P = 0.002 for TIMI flow, P = 0.014 for MBG ) values in the NRF group were significantly greater than those in the reflow group.
Angiographic findings according to reflow grouping are shown in Tables 3 and 4 .
In-hospital mortality and MACEs were also significantly higher in the NRF group. Similarly, inhospital cardiogenic shock, severe ventricular arrhythmia, and cardiopulmonary resuscitations were more common in the NRF patients (Tables 5 and 6 ).
Multivariate binary forward stepwise logistic regression analysis revealed that a high level of TRI was an independent predictor of NRF according to MBG flow (P = 0.003 B = -0.035, Exp B = 0966, 95% CI, 0.944-0.988).
Discussion
In the present study we showed that increased TRI, TRS, and GRS on admission were significantly associated with the development of angiographic NRF phenomenon in patients with acute STEMI who underwent p-PCI. Moreover, TRI was a significant and independent predictor of NRF. We also showed the Killip class.
Primary PCI is the recommended treatment for patients with acute STEMI. In 2008 the Stent for Life (SFL) initiative was launched by the European Association of Percutaneous Cardiovascular Interventions and EuroPCR in partnership with the European Society of Cardiology Working Group on Acute Cardiac Care and country-specific national cardiac societies. The aim was to promote the prioritization of PCI treatment for those who will benefit most, namely STEMI patients. The following countries are currently participating: Bulgaria, Egypt, France, Greece, Italy, Portugal, Romania, Serbia, Spain, and Turkey (26) . Preliminary reports suggest that major increases have been seen in the numbers of p-PCI treatments performed, with some countries reporting very significant increases in p-PCI use between 2008 and 2010. Improvements in STEMI mortality rates have also been observed. The number of p-PCI treatments performed in Europe has steadily increased over the past decade. However, a European survey from 2007 reported that only 40%-45% of European STEMI patients were treated with p-PCI, with large variations in treatment availability between countries (27) . The challenges of introducing new technologies into clinical practice can be substantial and include a complex mix of medical, organizational, patient-related, regulatory, and economic factors (28) .
There are 207 PCI capable centers in Turkey, shared among government hospitals, university hospitals, and private hospitals. P-PCI is performed 24/7 in 82 of the 207 centers. In March 2011, the Ministry of Health declared p-PCI as the first choice treatment for STEMI patients nationally, if transport time is less than 90 min. Since Turkey joined the SFL initiative, the number of p-PCI performed has increased significantly in ten pilot cities. In 2010, 85% of STEMI patients were treated with p-PCI. In addition, a STEMI network was created with collaboration between a number of invasive centers, noninvasive hospitals, ambulances, and emergency systems (26) .
Rapid restoration of coronary flow to the jeopardized myocardium has become an essential part of therapy after STEMI. P-PCI has also been found to significantly improve the survival of these patients (29) . Despite an open IRA, breakdown of obstruction to the coronary microvasculature can markedly decrease blood flow to the infarct zone. This effect is known as the NRF phenomenon (30, 31) . Coronary flow decreases in elderly patients, menopausal women, and patients with coronary risk factors (32) . This phenomenon is strongly correlated with shortand long-term morbidity and mortality in the settings of STEMI (33) . In our study, we showed that NRF was significantly related to in-hospital mortality and MACEs. The pathophysiology of the NRF phenomenon has not been fully clarified and its etiology appears to be multifactorial. Some of the contributing factors in the occurrence of NRF are distal atherothrombotic embolization, mechanical microvascular leukocytes, platelet plugs in situ thrombosis, (46) 37 (57) 0.027 RCA, n (%)
114 (37) 25 (39) CX, n (%) 53 (17) 31 (4) Number of coronary arteries narrowed 1 vessel, n (%) 134 (44) 24 (37) 0.299 >1 vessel n, (%)
171 (56) 41 (63) CX, circumflex coronary artery; LAD, left descendant coronary artery; RCA, right coronary artery. Table 4 . Angiographic findings of patients for MBG after primary PCI.
Reflow
No-reflow P value
Culprit lesion LAD, n (%) 153 (87) 23 (13) 0.097 RCA, n (%)
119 (86) 20 (14) CX, n (%) 54 (96) 2 (4) Number of coronary arteries narrowed 1 vessel, n (%) 143 (91) 15 (9) 0.175 >1 vessel n, (%) 182 (86) 30 (14) CX, circumflex coronary artery; LAD, left descendant coronary artery; RCA, right coronary artery. Table 5 . In-hospital adverse outcomes of patients TIMI flow after primary PCI.
Reflow No-reflow P value
In-hospital MACE, n (%) 56 (17) 28 (44) <0.001
Advanced Heart Failure, n (%) 17 (6) ischemic endothelial edema and damage, vasospasm, free oxygen radicals, and susceptibility of the coronary microcirculation to injury (9, 34, 35) . The close interplay between inflammation, coagulation, and atherosclerosis progression has become a field of intensive research. An increased inflammatory activity in the setting of STEMI may be one of the underlying NRF mechanisms. In fact, an elevated leukocyte-platelet interaction at the site of the plaque rupture may play a negative role in distal myocardial reperfusion by activating further inflammation. Botto et al. (36) showed an increased leukocyte-platelet functional interaction in STEMI at the site of plaque rupture relative to the systemic circulation, which may be one of the pathogenic mechanisms liable for NRF phenomenon. Thus, both locally increased inflammatory markers and leukocyte-platelet coaggregates at the site of the plaque rupture may be pathogenic mechanisms responsible for the angiographic NRF phenomenon after p-PCI in STEMI. Effective risk stratification is integral to the management of patients with ACS (37) . Even among patients with STEMI for whom initial therapeutic options are well-defined, patient risk characteristics can affect early therapeutic decision making (38) (39) (40) . There are few models that have integrated weighing information from multivariate regression in a fashion similar to the TRS, TRI, and GRS. The GRS has been recognized as a validated predictor of adverse cardiovascular disease events (19, 41) . GRS includes some variables, but does not include the properties of coronary lesion and inflammatory markers. The TRS for STEMI is a clinical stratification calculated with data obtained from hospital presentations that can easily classify low-and high-risk patients (42) . The TRS was validated prospectively in various studies. The analysis was subsequently validated in an unselected patient population in the National Registry of Myocardial Infarction (43) and showed a strong predictive value for mortality in patients treated with thrombolytic therapy (44) . TRS has been shown to be a predictor of MACEs in patients with STEMI (18) . The TRS serves as a prognostic calculator that discriminates high-risk patients with a combination of baseline variables that are part of the routine medical evaluation (22) . Moreover, the relationship between TRS and the severity of CAD has been shown in several studies. TRS was compared with the results of coronary angiography in 683 patients with NSTE-ACS; for each increased risk category, the 3-vessel disease was shown to be more frequent (1) . In the PRISM-PLUS study of 1491 patients with ACS, it was shown that there were more severe coronary lesions and left main coronary lesions in patients with high TRS compared with those with low TRS (45) . The TRS reliably identified patients who were at high risk, while maintaining good discriminatory capacity in the low-risk range, where smaller absolute differences are more likely to impact clinical decisions. The TRS includes some variables, but does not include inflammatory markers and the properties of coronary lesions. Another one of the important scoring systems used in risk stratification in patients with ACS is TRI. It has been shown to be useful and helpful in many studies with large patient populations. It was derived from observed risk relations among 13,253 patients enrolled in the Intravenous NPA for the treatment of infarcting myocardium early (In TIME II) randomized trial of lanoteplase versus alteplase as reperfusion therapy for STEMI (46) . The prognostic discriminatory capacity of this index was demonstrated (15, 16, 46) . The TRI was a strong and independent predictor of mortality at 24 h. It was validated in an external data set of STEMI patients from the TIMI-9 trials that showed both a high discriminatory capacity and concordance between the observed 30-day mortality and the predictions based on the In TIME II data (47). Rathore et al. (48) focused on this very point after evaluating the discrimination and calibration performance of the TRI in a community-based cohort of elderly patients taken from the Cooperative Cardiovascular Project. We applied the TRS, TRI, and GRS for STEMI in a group of patients who underwent p-PCI and showed that an increase in these scores was associated with increased frequency of angiographic NRF. To our knowledge, the relationship of TRI, TRS, and GRS with NRF for STEMI has not been previously investigated. Our results demonstrated for the first time the predictive value of these scores for NRF in patients with STEMI. In the present study, we think that with the help of the calculation of these scores in patients admitted to the emergency department with ACS, information about NRF of the CAD may be obtained.
Some limitations of our study include its retrospective nature and relatively small number of patients. Our study's population was also from a single center. Due to a male dominance in the patients in our study, the results may not be applicable to female patients.
The TRI, GRS, and TRS are routinely used for stratification of patients with ACS. Our study showed that these scores were significantly associated with NRF in patients with STEMI. We think that these findings can guide further clinical practice.
